CryoPort 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Cryoport reported 3rd quarter 2026 revenue of $50.2 million, up 14% year over year, with all revenue figures referring to continuing operations.
- Life Sciences Services revenue increased 18% and represented 57% of total company revenue; revenue from commercial cell and gene therapy clients increased 20%.
- Life Science Products revenue grew 8%, with demand from animal health customers and increased demand for the Fusion line of cryogenic freezers.
- Cryoport ended the quarter supporting 23 commercial therapies and had a record clinical trial pipeline of 788 trials, a net increase of 43 over the prior year, including 99 in phase 3.
- Adjusted EBITDA was positive $1.1 million for the quarter, a $1.8 million improvement year over year and the company’s 2nd consecutive quarter of positive adjusted EBITDA.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
As a reminder, this call is being recorded. I will now turn the call over to your host, Todd Fromer, from KCSA Strategic Communications.
Please go ahead. Thank you, operator.
Before we begin today, I would like to remind everyone that this conference call contains certain forward-looking statements. All statements that address our operating performance, events, or developments that we expect or anticipate occurring in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and not on information currently available to our management team. Our management team believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, except as required by law.
In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events, and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Item 1A, Risk Factors, and elsewhere in our annual report on Form 10-K filed with the Securities and Exchange Commission, and those described from time to time in the other reports which we file with the Securities and Exchange Commission. As a reminder, Cryoport has uploaded their third quarter 2026 in-review document to the main page of their Cryoport, Inc. website. This document provides a review of Cryoport's financial and operational performance and a general business outlook.
Before I turn the call over to Jerry, please note that because of the strategic partnership that has been established with DHL Group and the related sale of CRYOPDP to DHL in June 2025, CRYOPDP's financials, which were previously a part of Cryoport's Life Sciences Services reportable segment, are now presented as discontinued operations. Please note that unless otherwise indicated, all revenue figures discussed today will refer to continuing operations. This includes Cryoport's fiscal year 2026 revenue guidance. It is now my pleasure to turn the call over to Mr. Jerrell Shelton, Chief Executive Officer of Cryoport. Jerry, the floor is yours.
Thank you, Todd. Good afternoon, everyone. With me today is our Chief Financial Officer, Robert Stefanovich, our Chief Scientific Officer, Dr. Mark Sawicki, and our Vice President of Corporate Development and Investor Relations, Thomas Heinzen. I am pleased to report that Cryoport delivered another strong quarter with revenue of $50.2 million, representing a 14% year-over-year growth. Life Sciences Services continued to be a key growth driver, with revenue increasing 18% and representing 57% of our total company revenue. Within services, our core cell and gene therapy business delivered very strong results, with revenue from commercial cell and gene therapy clients increasing 20%. These results reflect the growing number of patients worldwide receiving cell and gene therapy treatments and the continued adoption of our integrated supply chain solutions.
During the third quarter, Cryoport continued to expand its leadership position within the cell and gene therapy ecosystem, ending the quarter supporting 23 commercial therapies, as our client, Replimune, received accelerated FDA approval for TUDRIQEV for the treatment of adults with unresectable advanced cutaneous melanoma, a skin cancer that has spread too widely or deeply to be safely or completely removed with surgery. We also concluded the quarter with a record clinical trial pipeline of 788 clinical trials, a net increase of 43 clinical trials over the prior year, with 99 of these trials being in phase III. 99 of these trials in phase III. We believe our industry-leading position will continue to drive commercial revenue as these therapies receive additional regulatory approval.
Based on the information we have today, for the remainder of the year, we expect another five possible BLA/MAA application filings, two potential new therapy approvals, and one additional supplemental approval for geographic expansion. It is important to note that both of these potential new therapy approvals have received PDUFA dates from the FDA and are scheduled for the fourth quarter of this year. We also posted solid life science products revenue, with growth of 8% for the quarter, reflecting MVE Biological Solutions' position as the global leader in cryogenic systems. Specific revenue contributors in the third quarter included strong demand for animal health customers, as well as increasing demand for our Fusion line of cryogenic freezers. MVE continues to be the industry leader and a consistent cash flow generator, while also providing support and meaningful synergies with our Life Sciences Services business.
Our integrated end-to-end platform across the life sciences ecosystem, combined with disciplined execution and increasing utilization of our global supply chain center network, positions us to scale with the industry efficiently and exercise operating leverage as we continue to advance towards sustained profitability. This was also shown in our financial results, as we report in our second consecutive quarter of positive adjusted EBITDA of $1.1 million for the quarter. A $1.8 million improvement year over year. With our progress to date on our pathway to profitability initiative, we believe our financial results will continue to improve. During the third quarter, our global supply chain center in Paris, France, received ISO 9001 and ISO 21973 certifications. As a result, Cryoport Systems received the Healthcare and Pharmaceutical Supply Chain Excellence Award at the 2026 Supply Chain Excellence Awards USA.
This was largely in recognition of becoming the first global supply chain solutions provider to achieve ISO 21973 certification, which is the first international standard developed specifically to address the transportation risk associated with human cells for therapeutic use. We are extremely proud to achieve these certifications and industry recognition. Taking these initiatives and achievements into account, along with our strong year-to-date performance, combined with our increased visibility, expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and healthy demand for MVE's industry-leading products, we are well-positioned to meet our 2026 financial goals. Therefore, we are raising our full year 2026 revenue outlook to $197 million-$199 million. This concludes my remarks for today. Now I will ask the operator to open the floor for your questions.
Thank you. Ladies and gentlemen, we will now begin the question-and-answer session. Should you have a question, please press the star key followed by the number 1 on your touchtone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press the star key followed by the number 2. One moment, please, while we assemble the queue. Your first question comes from Puneet Souda at Leerink Partners.
Please go ahead. Hi, this is Philip on for Puneet.
Thanks for the question, and congrats on the quarter. I wanted to ask about guidance. By our math, you raised the midpoint by $4 million on a $1.6 million beat, implying 4Q of $50 million-$52 million. Question is, what drives the 4Q step-up in services versus products, and how much macro caution is still embedded in the range?
I think overall, what we did when we looked at guidance for the full year is really to give a prudent guidance for the full year. We had very, very strong results really over the last three quarters in terms of revenue growth and also expansion of our bottom line. Looking into Q4 and looking at the growth prospects, we think this was the right level of guidance to provide for the year. It looks at a 12% growth year-over-year, and there is certainly upside potential for that as well.
Got it. That makes sense. Follow-up question on pipeline expectations. I think in August, I believe you expected 11 more filings and five approvals this year. Correct me if I am wrong, but now it is two filed, five more possible, and two approvals. The question is, what moved exactly? Is it FDA timing or sponsor decisions? Separately, is it safe to assume that the two decisions expected in 4Q are the two multiple myeloma drugs? I think both have PDUFA dates in December.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
